Recently, the world witnessed the approval of the world’s first two iPSC-derived medicines, as Japan’s health ministry panel authorized their commercialization on February 19, 2026. The approved therapies are ReHeart, developed by Cuorips Inc., a regenerative medicine company spun out of research at Osaka University, and Amchepry, developed by Sumitomo Pharma Co., Ltd. in collaboration with Racthera Inc. [Read more…]
Key Events in the Evolution of iPSC Products that You Need to Know
Developing induced pluripotent stem cell (iPSC) products requires a thorough understanding of the evolution of iPSC research advances. Because the cell type was recently discovered in 2006, the following presents a decade-long timeline of key events in the discovery and evolution of induced pluripotent stem cell products.
The research events below drove forward interest in the use of iPSCs for basic research and clinical applications. These events are the reason that the first clinical trial involving the implantation of iPSCs into humans was initiated in 2013, to assess the capacity of the cell type to treat loss of eyesight due to macular degeneration.
For this reason, stem cell company executives and stem cell industry investors will be better suited to make future decisions about iPSC products if they have a historical understanding of the recent past and the rate at which research advances with the cell type accelerated. [Read more…]
Gameto Licenses Foundational Meiosis IP from Harvard to Advance Human Ovary-in-a-Dish Platform
Newly licensed intellectual property enables genetic induction of early meiosis, further strengthening Gameto’s best-in-class platform for modeling human ovarian development and disease
AUSTIN, Texas, Jan. 29, 2026 –– Gameto, a clinical-stage biotechnology company advancing cell engineering solutions for women’s health, announced that it has exclusively licensed additional intellectual property from Harvard University related to the induction of meiosis in human cells. The IP builds upon prior work conducted under Gameto’s sponsored research agreement with George Church’s laboratory at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering.
Cytonome Congratulates Sumitomo Pharma on Regulatory Approval for Regenerative Medicine Therapy for Parkinson’s disease
March 11, 2026, Lexington, MA / United States — Cytonome-ST today congratulated Sumitomo Pharma Co., Ltd. following the company’s announced receipt of regulatory approval for the world’s first iPS cell-derived regenerative medicine for the treatment of Parkinson’s disease.
https://www.sumitomo-pharma.com/news/20260306.html [Read more…]
Advantages and Disadvantages of Induced Pluripotent Stem Cells
When analyzing the induced pluripotent stem cell (iPSC) market, the technical aspects can often appear to be confusing. However, if you focus on a few key points of understanding, you’ll be able to understand key attributes that define the cell type, as well as their advantages and disadvantages. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 19
- Next Page »